公开(公告)号：US06458791B1

公开(公告)日：2002-10-01

申请号：US10040475

申请日：2002-01-09

Applicant: Thomas P. Jerussi ,  Chrisantha H. Senanayake ,  Paul D. Rubin ,  Yaping Hong ,  Roger A. Bakale ,  Tingjian Xiang ,  Fran A. McConville

Inventor： Thomas P. Jerussi ,  Chrisantha H. Senanayake ,  Paul D. Rubin ,  Yaping Hong ,  Roger A. Bakale ,  Tingjian Xiang ,  Fran A. McConville

IPC: A61K31495

CPC classification number: A61K31/4985 ,  A61K31/498 ,  C07B2200/07 ,  C07D487/04

Abstract: The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone.

Abstract translation: 本发明涉及包含外消旋的N-去甲基佐氮克隆，光学纯的（+） - N-去甲基佐匹克隆和光学纯的（ - ） - N-去甲基佐匹克隆的组合物，其用于治疗和预防哺乳动物的疾病和病症。 本发明进一步涉及制备N-去甲基异佐匹克隆，光学纯的（+） - N-去甲基佐匹克隆和光学纯的（ - ） - N-去甲基异佐匹克隆的新方法。

公开(公告)号：US06458374B1

公开(公告)日：2002-10-01

申请号：US09238984

申请日：1999-01-28

Applicant: John R. McCullough ,  Paul D. Rubin

Inventor： John R. McCullough ,  Paul D. Rubin

IPC: A61F202

CPC classification number: A61K31/137 ,  A61K9/2018 ,  A61K9/2059 ,  A61K31/135

Abstract: Methods and compositions are disclosed utilizing the optically pure (+)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.

Abstract translation: 公开利用安非他酮的光学纯的（+）异构体来帮助戒烟，治疗吸烟和尼古丁成瘾以及治疗疼痛的方法和组合物，包括但不限于慢性疼痛，神经性疼痛和反射性交感神经营养不良 ，以及其他疾病如发作性睡病，慢性疲劳综合征，纤维肌痛，季节性情感障碍和经前期综合征，同时避免与外消旋安非他酮相关的不良影响。

公开(公告)号：US06353005B1

公开(公告)日：2002-03-05

申请号：US09507965

申请日：2000-02-22

Applicant: Paul D. Rubin ,  Timothy J. Barberich

Inventor： Paul D. Rubin ,  Timothy J. Barberich

IPC: A61K31445

CPC classification number: A61K31/135 ,  A61K31/415 ,  A61K31/445 ,  A61K38/16 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention relates to methods and compositions for the prevention, treatment, or management of gastrointestinal disorders or symptoms thereof, employing two or more agents or compounds to provide a triple site action on 5-HT3 receptors, 5-HT4 receptors, and at least one of H2 receptors and proton pumps.

Abstract translation: 本发明涉及用于预防，治疗或管理胃肠道疾病或其症状的方法和组合物，其采用两种或多种药剂或化合物来提供对5-HT 3受体，5-HT 4受体和至少一种 的H2受体和质子泵。

公开(公告)号：US06248308B1

公开(公告)日：2001-06-19

申请号：US09059572

申请日：1998-04-14

Applicant: Paul D. Rubin

Inventor： Paul D. Rubin

IPC: A61K912

CPC classification number: A61K45/06 ,  A61K31/445 ,  Y10S514/826

Abstract: Methods and pharmaceutical compositions employing norastemizole and a leukotriene inhibitor for the treatment or prevention of inflammation or allergic disorders, such as asthma or the symptoms thereof. Also included are methods and compositions employing norastemizole and a decongestant for the treatment or prevention of inflammation or allergic disorders, such as asthma or the symptoms thereof.

Abstract translation: 使用诺尔阿司咪唑和白三烯抑制剂用于治疗或预防炎症或过敏性疾病如哮喘或其症状的方法和药物组合物。 还包括使用诺尔阿司咪唑和减充血剂用于治疗或预防炎症或过敏性疾病如哮喘或其症状的方法和组合物。

公开(公告)号：US06194431B1

公开(公告)日：2001-02-27

申请号：US09059570

申请日：1998-04-14

Applicant: Paul D. Rubin

Inventor： Paul D. Rubin

IPC: A01N4342

CPC classification number: A61K45/06 ,  A61K31/445 ,  A61K31/47 ,  A61K31/475 ,  A61K31/41 ,  A61K31/405 ,  A61K31/40 ,  A61K2300/00

Abstract: Methods and pharmaceutical compositions employing a terfenadine metabolite and a leukotriene inhibitor for the treatment or prevention of inflammation or allergic disorders, such as asthma, or symptoms thereof. Also included are methods and compositions employing a terfenadine metabolite, a leukotriene inhibitor, and a decongestant for the treatment or prevention of inflammation or allergic disorders, such as asthma, or symptoms thereof.

Abstract translation: 使用特非那定代谢物和白三烯抑制剂用于治疗或预防炎症或过敏性疾病如哮喘或其症状的方法和药物组合物。 还包括使用特非那定代谢物，白三烯抑制剂和减充血剂用于治疗或预防炎症或过敏性疾病如哮喘或其症状的方法和组合物。

公开(公告)号：US5962464A

公开(公告)日：1999-10-05

申请号：US110367

申请日：1998-07-06

Applicant: Dean A. Handley ,  Paul D. Rubin

Inventor： Dean A. Handley ,  Paul D. Rubin

IPC: A61K31/445 ,  A61K31/4545 ,  A61K45/06 ,  A61P11/06 ,  A61P37/08 ,  A61P43/00 ,  A61K31/44

CPC classification number: A61K45/06 ,  A61K31/445 ,  A61K31/4545 ,  Y10S514/826 ,  Y10S514/864

Abstract: Methods utilizing descarboethoxyloratadine ("DCL"), for the treatment of allergic disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines. Also included are methods for the treatment of allergic asthma using DCL and either a decongestant or a leukotriene inhibitor, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines. The invention also encompasses the administration of DCL in a nasal or oral spray.

Abstract translation: 利用去甲氧基吡咯烷（“DCL”）治疗过敏性疾病的方法，同时避免与其他非镇静性抗组胺药相关的不利副作用的伴随责任。 还包括使用DCL和减充血剂或白三烯抑制剂治疗过敏性哮喘的方法，同时避免与其它非镇静性抗组胺药相关的副作用的伴随的责任。 本发明还包括以鼻腔或口腔喷雾剂施用DCL。